Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Merus NV MRUS

Healthcare Biotechnology

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRUS)

Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

GlobeNewswire January 2, 2019

The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

Benzinga.com December 28, 2018

Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update

GlobeNewswire December 27, 2018

Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals

GlobeNewswire December 20, 2018

Merus to Present at the Jefferies 2018 London Healthcare Conference

GlobeNewswire November 8, 2018

Merus to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 27, 2018

Merus Strengthens Team with Key Appointments

GlobeNewswire September 27, 2018

Merus to Participate in Citi’s 13th Annual Biotech Conference

GlobeNewswire August 30, 2018

Merus Announces Formation of a Scientific Advisory Board

GlobeNewswire August 22, 2018

Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 21, 2018

Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results

GlobeNewswire August 10, 2018

Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 7, 2018

Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

GlobeNewswire July 26, 2018

Merus to Present at the Jefferies 2018 Healthcare Conference

GlobeNewswire May 31, 2018

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

GlobeNewswire May 24, 2018

Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell

GlobeNewswire May 15, 2018

Merus N.V. to Host Earnings Call

Accesswire April 26, 2018

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018

GlobeNewswire April 19, 2018

Analysis: Positioning to Benefit within HudBay Minerals, IRHYTHM TECH, TechTarget, Mercury, Merus N.V, and Tecnoglass — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire April 9, 2018

Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer

GlobeNewswire March 20, 2018